US 10,376,535 B2
Therapy for malignant disease
Richard G. Moore, Victor, NY (US); Rakesh K. Singh, Barrington, RI (US); and Naohiro Yano, Lincoln, RI (US)
Assigned to University of Rochester, Rochester, NY (US)
Appl. No. 15/561,466
Filed by UNIVERSITY OF ROCHESTER, Rochester, NY (US)
PCT Filed Mar. 28, 2016, PCT No. PCT/US2016/024566
§ 371(c)(1), (2) Date Sep. 25, 2017,
PCT Pub. No. WO2016/154629, PCT Pub. Date Sep. 29, 2016.
Claims priority of provisional application 62/138,836, filed on Mar. 26, 2015.
Prior Publication US 2018/0117075 A1, May 3, 2018
Int. Cl. A61K 48/00 (2006.01); C07H 21/02 (2006.01); A61K 31/7105 (2006.01); A61K 45/06 (2006.01); A61K 31/5025 (2006.01); A61K 31/58 (2006.01); A61K 31/713 (2006.01); A61P 35/00 (2006.01); A61K 33/24 (2019.01); A61K 45/00 (2006.01); G01N 33/574 (2006.01)
CPC A61K 31/7105 (2013.01) [A61K 31/5025 (2013.01); A61K 31/58 (2013.01); A61K 31/713 (2013.01); A61K 33/24 (2013.01); A61K 45/05 (2013.01); A61K 45/06 (2013.01); A61K 48/0016 (2013.01); A61K 48/0066 (2013.01); A61P 35/00 (2018.01); G01N 33/57484 (2013.01); A61K 2300/00 (2013.01); C12N 2310/11 (2013.01); C12N 2310/122 (2013.01)] 11 Claims
 
1. A method of suppressing tumor cell proliferation in a subject comprising: concurrently or sequentially inhibiting
(a) the activity or level of human epididymal secretory protein E4 (HE4) in said tumor cell; and
(b) the activity or level of one or more immune checkpoint inhibitors (ICIs) in the cell, thereby suppressing tumor cell proliferation in said subject,
wherein the HE4 level in said tumor cell is >400 pM,
wherein said level of HE4 in said tumor cell is inhibited by administering an effective amount of an HE4 inhibitor to said tumor cell,
wherein the ICI comprises PD-L1,
wherein the level of said one or more ICIs in said tumor cell is inhibited by administering an effective amount of an ICI inhibitor to said tumor cell, and
wherein said tumor cell is a Müllerian cancer cell.